These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 8851387)
1. [Combination effect of vancomycin and cefpirome against methicillin-resistant Staphylococcus aureus in vitro--antimicrobial activities in postantibiotic phase]. Hasegawa H; Kanai A; Otoguro K; Shimizu K Kansenshogaku Zasshi; 1996 Feb; 70(2):151-60. PubMed ID: 8851387 [TBL] [Abstract][Full Text] [Related]
2. [Combination effect between panipenem and vancomycin on highly methicillin-resistant Staphylococcus aureus]. Fukuoka T; Domon H; Kakuta M; Ishii C; Hirasawa A; Utsui Y; Ohya S; Yasuda H Jpn J Antibiot; 1997 Apr; 50(4):411-9. PubMed ID: 9192249 [TBL] [Abstract][Full Text] [Related]
3. In-vitro bactericidal activity of cefpirome and cefamandole in combination with glycopeptides against methicillin-resistant Staphylococcus aureus. Bergeret M; Raymond J J Antimicrob Chemother; 1999 Feb; 43(2):291-4. PubMed ID: 11252338 [TBL] [Abstract][Full Text] [Related]
4. In-vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative staphylococci. Raymond J; Vedel G; Bergeret M J Antimicrob Chemother; 1996 Dec; 38(6):1067-71. PubMed ID: 9023655 [TBL] [Abstract][Full Text] [Related]
5. [Bacteriological evaluation of combined effects of vancomycin and beta-lactams. I. Results against methicillin-resistant Staphylococcus aureus]. Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S Jpn J Antibiot; 1993 Nov; 46(11):939-45. PubMed ID: 8309069 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro]. Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148 [TBL] [Abstract][Full Text] [Related]
7. [Combination effect of arbekacin and cefepime on mixed culture of MRSA and P. aeruginosa]. Araake M; Hara T; Miyata A; Tani M; Ogawa H Jpn J Antibiot; 2001 Feb; 54(2):69-78. PubMed ID: 11338680 [TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524 [TBL] [Abstract][Full Text] [Related]
9. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus. Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411 [TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of TOC-50, a new parenteral cephalosporin against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Nomura S; Hanaki H; Unemi N Chemotherapy; 1996; 42(4):253-8. PubMed ID: 8804792 [TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo activity of cefpirome (HR 810) against methicillin-susceptible and -resistant Staphylococcus aureus and Streptococcus faecalis. Eng RH; Cherubin CE; Smith SM; Buccini F; Harris R J Antimicrob Chemother; 1989 Mar; 23(3):373-81. PubMed ID: 2499565 [TBL] [Abstract][Full Text] [Related]
14. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. Dilworth TJ; Leonard SN; Vilay AM; Mercier RC Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667 [TBL] [Abstract][Full Text] [Related]
15. The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. Seibert G; Isert D; Klesel N; Limbert M; Markus A; Schrinner E J Antimicrob Chemother; 1992 Apr; 29 Suppl A():25-30. PubMed ID: 1601753 [TBL] [Abstract][Full Text] [Related]
16. Postantibiotic effect and postantibiotic sub-MIC effect of LTX-109 and mupirocin on Staphylococcus aureus blood isolates. Saravolatz LD; Pawlak J; Martin H; Saravolatz S; Johnson L; Wold H; Husbyn M; Olsen WM Lett Appl Microbiol; 2017 Nov; 65(5):410-413. PubMed ID: 28802058 [TBL] [Abstract][Full Text] [Related]
17. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Aeschlimann JR; Hershberger E; Rybak MJ Antimicrob Agents Chemother; 1999 Aug; 43(8):1914-8. PubMed ID: 10428912 [TBL] [Abstract][Full Text] [Related]
18. In vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis. Lozniewski A; Lion C; Mory F; Weber M J Antimicrob Chemother; 2001 Jan; 47(1):83-6. PubMed ID: 11152435 [TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of methicillin-resistant Staphylococcus aureus to imipenem and other antimicrobial agents. Ishag AJ; Durgham SM; Shibl AM Chemioterapia; 1987 Aug; 6(4):261-3. PubMed ID: 3477333 [TBL] [Abstract][Full Text] [Related]
20. In vitro bactericidal activity of cefpirome in combination with vancomycin against Staphylococcus aureus and coagulase-negative Staphylococcus. Raymond J; Vedel G; Bergeret M Diagn Microbiol Infect Dis; 1998 Jul; 31(3):481-3. PubMed ID: 9635241 [No Abstract] [Full Text] [Related] [Next] [New Search]